Vesselon develops patentable drug co-formulations using an FDA-approved, biophysically activated lipid microsphere and self-assembling liposomes. Their platform enhances the biodistribution and efficacy of drugs by targeting, delivering, and releasing pharmaceuticals with unprecedented levels of efficacy. Vesselon extends the lifecycle of virtually any drug, enabling drug firms to grow market share, protect portfolios, and supercharge pipeline products. The company focuses on producing an endless stream of proprietary pharmaceuticals through innovative drug formulations and biophysical interactions.